Delix: taking the psychedelic out of psychedelics

With $100 million in financing from Artis Ventures, RA Capital and OMX Ventures, Delix is developing psychedelics-inspired small molecules that induce plasticity in the brain without evoking the class’ hallucinogenic effects.

Enthusiasm for psychedelic drugs as tools to treat depression and other mental health conditions has led to a deluge of new companies exploring the space — from classic psychedelics such as “magic mushrooms” and LSD to lesser-known and newly invented tryptamines and empathogens. ...